Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.44 |
| ▸ | FEN1 | P39748 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | TYR | P14679 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.42 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL47580 | 0.89 | CA2 (0.68) | CA2GABRA1GABRB2ALOX5APFEN1 | |
| SCHEMBL30938109 | 0.89 | CA2 (0.68) | CA2GABRA1GABRB2ALOX5APFEN1 | |
| SCHEMBL17363913 | 0.80 | CA2 (0.52) | CA2GABRA1GABRB2ALOX5APFEN1 | |
| SCHEMBL29488108 | 0.79 | CA2 (0.56) | CA2GABRA1GABRB2ALOX5APFEN1 | |
| SCHEMBL3169896 | 0.79 | CA2 (0.56) | CA2GABRA1GABRB2ALOX5APFEN1 | |
| SCHEMBL2210615 | 0.77 | CA2 (0.76) | CA2GABRA1GABRB2CA1ALDH1A1 | |
| Lithium Ion SCHEMBL4307076 | 0.77 | CA2 (0.54) | CA2GABRA1GABRB2ALOX5APFEN1 | |
| SCHEMBL3461711 | 0.77 | GABRA1 (0.64) | CA2GABRA1GABRB2CA1ALDH1A1 | |
| SCHEMBL11477439 | 0.76 | CA2 (0.59) | CA2GABRA1GABRB2ALOX5APFEN1 | |
| SCHEMBL6229514 | 0.75 | CA2 (0.52) | CA2GABRA1GABRB2ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | ASCENDIS PHARMA A/S (DK) | 2021-11-04 | — | — | US | disclosed |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | ASCENDIS PHARMA A/S (DK) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | CD44, HPSE, MMP13 | CA2 1811/4885GABRA1 1608/4885GABRB2 3558/4885 |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | H1-10, PM20D2, ELANE | CA2 992/4885GABRA1 4041/4885GABRB2 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.